Bristol-Myers Squibb's Opdivo has been recommended as a treatment for around 3,000 people with rare forms of gastro-oesophageal cancer via the NHS in England and Wales. In final guidance ...

Enhertu already has seven FDA approvals across breast cancer, gastric cancer, non-small cell lung cancer (NSCLC), and ...

Zolbetuximab (Vyloy) with fluoropyrimidine- and platinum-based chemotherapy is not normally available on the NHS for untreated, gastric or gastro-oesophageal junction adenocarcinoma in adults that is: ...